Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
CORAL GABLES, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024.
| Conference Call and Webcast Information: | ||
| Date: | Thursday, November 7, 2024 at 4:30 PM ET | |
| Participant Dial-in (US): | 1-800-717-1738 | |
| Participant Dial-in (International): | 1-646-307-1865 | |
| Conference ID Code: | 60579 | |
| Webcast Access: | Click Here | |
A replay of the webcast will be available in the Investors section of the Relmada website athttps://www.relmada.com/investors/ir-calendar.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017 (esmethadone), is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more atwww.relmada.com.
Investor Contact:Tim McCarthyLifeSci AdvisorsTim@lifesciadvisors.com
Released November 4, 2024